Rentschler Biopharma and Coriolis Pharma announced a collaboration to offer integrated services from early formulation through commercial biologics manufacturing, combining formulation expertise with bioprocess development and manufacturing capabilities. The offering targets clients seeking connected, science‑driven solutions across the biopharma value chain. Separately, Recipharm Advanced Bio began process performance qualification (PPQ) for Infant Bacterial Therapeutics’ lead live biotherapeutic product IBP‑9414 at its Cuxhaven microbial facility, advancing commercial readiness for what could be the first globally marketed LBP. Both moves reflect an industry focus on building end‑to‑end capacity for complex modalities—live biotherapeutics and advanced biologics—and highlight the rising role of CDMOs/CRDOs in accelerating time to market.